What is Marcus & Millichap's sars liability?

Marcus & Millichap (MMI) reported sars liability of $863K in Q1 2026.

How has Marcus & Millichap's sars liability changed year-over-year?

Marcus & Millichap's sars liability decreased by 68.9% year-over-year, from $2.77M to $863K.

What is the long-term trend for Marcus & Millichap's sars liability?

Over 5 years (2020 to 2025), Marcus & Millichap's sars liability has grown at a 5.3% compound annual growth rate (CAGR), from $2.16M to $2.8M.

Marcus & Millichap MMI SARs liability

Other financials

Income statement

See full

Revenue$171.5M+18.2%

Operating income-$5.8M+67.4%

Net income-$3.1M+29.9%

EPS (diluted)-$0.08+27.3%

Balance sheet

See full

Cash & equivalents$136.5M-8.8%

Total debt$75.0M-10.6%

Total equity$569.1M-7.9%

Total assets$755.0M-5.9%

Cash flow

See full

Operating cash flow-$27.6M+47.8%

CapEx$3.0M+99.5%

Free cash flow-$30.5M+43.8%

Valuation

See full

Market cap$1.12B-5.0%

Enterprise value$1.06B-4.9%

P/S1.4×-0.2×

Profitability

See full

Gross margin38.1%—

Operating margin-9.1%+59.1pp

Net margin-5%-19.8pp

FCF margin10.6%+8.7pp

Returns & leverage

See full

Return on equity-4.9%-44.5pp

Debt / equity0.1×0.0×

Current ratio2.6×-1.1×

Where this comes from

Reported directly by Marcus & Millichap in its filing.

Tagged under the XBRL concept mmi:StockAppreciationRightsLiabilityCurrent.

The official record: Marcus & Millichap’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Marcus & Millichap's sars liability.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Marcus & Millichap's sars liability?: Marcus & Millichap (MMI) reported sars liability of $863K in Q1 2026.
How has Marcus & Millichap's sars liability changed year-over-year?: Marcus & Millichap's sars liability decreased by 68.9% year-over-year, from $2.77M to $863K.
What is the long-term trend for Marcus & Millichap's sars liability?: Over 5 years (2020 to 2025), Marcus & Millichap's sars liability has grown at a 5.3% compound annual growth rate (CAGR), from $2.16M to $2.8M.